Organizations
- Revolution Medicines
Rasonque is the first approved therapy designed to inhibit multiple active forms of RAS, a major driver of pancreatic adenocarcinoma. The approval gives Revolution Medicines its first commercial medicine.
What happened
- The FDA approved Rasonque for adults with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy or cannot receive multiagent systemic therapy.
- The once-daily tablet targets multiple active forms of RAS.
- The FDA granted the approval to Revolution Medicines.
Why it matters
A first-in-class, multi-selective RAS inhibitor is now available for a cancer with historically limited treatment options.
Key details
- Medicine
- Rasonque (daraxonrasib)
- Indication
- Previously treated metastatic pancreatic adenocarcinoma, or patients unable to receive multiagent systemic therapy
- Company
- Revolution Medicines
What to watch
- Commercial availability, uptake, and post-approval safety reporting.
Event chronology
How the story developed
FDA approval
The FDA approved Rasonque for the indicated metastatic pancreatic-cancer population.
Evidence ledger
Sources behind this brief
- 01
- 02
- 03
- 04
- 05
- 06
- 07